PMID- 20364004
OWN - NLM
STAT- MEDLINE
DCOM- 20100507
LR  - 20100405
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 24
IP  - 2
DP  - 2010 Mar-Apr
TI  - Association of CCL2 and CCR2 gene variants with endometrial cancer in Turkish 
      women.
PG  - 243-8
AB  - Chemokines and their receptors play diverse roles in malignant tumor progression, 
      particularly as key mediators of tumor stroma interactions. C-C motif chemokine 
      ligand 2 (CCL2) also called monocyte chemoattractant protein-1 (MCP-1), belongs 
      to the C-C motif chemokine sub-family and is currently believed to mediate its 
      actions through one receptor, C-C motif chemokine receptor 2 (CCR2). CCL2 has 
      been identified as a major chemokine inducing the recruitment of macrophages in 
      human tumors, including those of the bladder, cervix, ovary, lung and breast. In 
      this study of Turkish women, the association of CCL2 A2518G and CCR2 V64I 
      polymorphisms with endometrial cancer was investigated using 50 endometrial 
      cancer patients and 211 controls. In our study, individuals with CCL2 A2518G GG 
      genotype showed a 6.7-fold increased risk for endometrial cancer (p<0.0001) and 
      individuals with CCL2 A2518G A allele had a 7.14-fold lower risk of endometrium 
      cancer (p<0.0001). Individuals carrying the CCR2 64I/64I genotype had a 4.13-fold 
      increased risk for endometrial cancer (p<0.0001). We also found that individuals 
      carrying the CCR2 wt allele had a 4.16-fold lower risk for endometrial cancer 
      (p=0.005). We observed that the CCL2 G: CCR2 64I haplotype frequency was 
      significantly higher in patients compared to controls (p=0.019). In conclusion, 
      we state that there appears to be an association between polymorphism of CCL2 and 
      its receptor CCR2 and endometrial cancer. To the best of our knowledge, this is 
      the first study to show such an association.
FAU - Attar, Rukset
AU  - Attar R
AD  - Department of Obstetrics and Gynecology, Yeditepe University Hospital, Istanbul, 
      Turkey.
FAU - Agachan, Bedia
AU  - Agachan B
FAU - Kuran, Sibel Bulgurcuoglu
AU  - Kuran SB
FAU - Cacina, Canan
AU  - Cacina C
FAU - Sozen, Seyma
AU  - Sozen S
FAU - Yurdum, Leman Melis
AU  - Yurdum LM
FAU - Attar, Erkut
AU  - Attar E
FAU - Isbir, Turgay
AU  - Isbir T
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCR2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Receptors, CCR2)
SB  - IM
MH  - Chemokine CCL2/*genetics
MH  - Endometrial Neoplasms/*genetics
MH  - Female
MH  - Gene Frequency
MH  - Genetic Variation
MH  - Genotype
MH  - Humans
MH  - Middle Aged
MH  - *Polymorphism, Genetic
MH  - Receptors, CCR2/*genetics
MH  - Turkey
EDAT- 2010/04/07 06:00
MHDA- 2010/05/08 06:00
CRDT- 2010/04/06 06:00
PHST- 2010/04/06 06:00 [entrez]
PHST- 2010/04/07 06:00 [pubmed]
PHST- 2010/05/08 06:00 [medline]
AID - 24/2/243 [pii]
PST - ppublish
SO  - In Vivo. 2010 Mar-Apr;24(2):243-8.